To include your compound in the COVID-19 Resource Center, submit it here.

SB623: Phase I/IIa started

SanBio began an open-label, U.S. Phase I/IIa trial to evaluate an intracranial injection

Read the full 138 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE